The RSVPreF3-AS01 vaccine elicits broad neutralization of contemporary and antigenically distant respiratory syncytial virus strains-Reference-Cited by-同舟云学术

The RSVPreF3-AS01 vaccine elicits broad neutralization of contemporary and antigenically distant respiratory syncytial virus strains

Published:2023-08-23 Issue:710 Volume:15 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Sacconnay Lionel¹^ORCID,De Smedt Jonathan¹^ORCID,Rocha-Perugini Vera¹^ORCID,Ong Edison¹,Mascolo Romuald¹,Atas Anne¹^ORCID,Vanden Abeele Carline²^ORCID,de Heusch Magali²^ORCID,De Schrevel Nathalie¹^ORCID,David Marie-Pierre²^ORCID,Bouzya Badiaa²^ORCID,Stobbelaar Kim³^ORCID,Vanloubbeeck Yannick¹,Delputte Peter L.³^ORCID,Mallett Corey P.⁴^ORCID,Dezutter Nancy²^ORCID,Warter Lucile¹^ORCID

Affiliation:

1. GSK, 1330 Rixensart, Belgium.

2. GSK, 1300 Wavre, Belgium.

3. Department of Biomedical Sciences and Infla-Med Centre of Excellence, University of Antwerp, 2610 Wilrijk, Belgium.

4. GSK, Rockville, MD 20850, USA.

Abstract

The RSVPreF3-AS01 vaccine, containing the respiratory syncytial virus (RSV) prefusion F protein and the AS01 adjuvant, was previously shown to boost neutralization responses against historical RSV strains and to be efficacious in preventing RSV-associated lower respiratory tract diseases in older adults. Although RSV F is highly conserved, variation does exist between strains. Here, we characterized variations in the major viral antigenic sites among contemporary RSV sequences when compared with RSVPreF3 and showed that, in older adults, RSVPreF3-AS01 broadly boosts neutralization responses against currently dominant and antigenically distant RSV strains. RSV-neutralizing responses are thought to play a central role in preventing RSV infection. Therefore, the breadth of RSVPreF3-AS01–elicited neutralization responses may contribute to vaccine efficacy against contemporary RSV strains and those that may emerge in the future.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Link

https://www.science.org/doi/pdf/10.1126/scitranslmed.adg6050

Reference60 articles.

1. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis

2. Global Disease Burden Estimates of Respiratory Syncytial Virus–Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis

3. Global distribution of respiratory syncytial virus A and B infections: a systematic review

4. Molecular epidemiology of respiratory syncytial virus

5. Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Respiratory syncytial virus immunoprophylaxis: Novel opportunities and a call for equity;Journal of Medical Virology;2024-02

2. All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design?;Vaccines;2024-01-18

3. A Mixture of T-Cell Epitope Peptides Derived from Human Respiratory Syncytial Virus F Protein Conferred Protection in DR1-TCR Tg Mice;Vaccines;2024-01-12

4. Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial;The Journal of Infectious Diseases;2023-12-14